EyePoint Pharmaceuticals Inc. buy Royal Bank of Canada
Start price
17.06.25
/
50%
€8.18
Target price
17.06.26
€24.24
Performance (%)
78.04%
Price
18.12.25
€14.15
Summary
This prediction is currently active. With a performance of 78.04% the BUY prediction by Royal_Bank_of_Canada is a big success. This prediction currently runs until 17.06.26. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| EyePoint Pharmaceuticals Inc. | 14.959% | 14.959% |
| iShares Core DAX® | -0.793% | 4.201% |
| iShares Nasdaq 100 | -2.376% | 0.857% |
| iShares Nikkei 225® | -2.701% | -0.147% |
| iShares S&P 500 | -1.689% | 1.244% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread EyePoint Pharmaceuticals Inc. diskutieren
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $28.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€9.59
06.11.25
06.11.25
€33.89
06.11.26
06.11.26
51.79%
18.12.25
18.12.25
